Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse

Neuropharmacology

Volumn 53, Issue 6, 2007, Pages 699-723

  Parsons, Chris G ^a   Stöffler, Albrecht ^a   Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Alzheimer's disease; Learning; LTP; Memantine; Memory; NMDA; Symptomatic

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BUNGAROTOXIN RECEPTOR; CISPLATIN; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; KAINIC ACID; KETAMINE; MAGNESIUM; MECAMYLAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOMELIDINE; PHENCYCLIDINE; SEROTONIN 3 RECEPTOR;

ALZHEIMER DISEASE; AVOIDANCE BEHAVIOR; BLOOD FLOW; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CHEMOTHERAPY INDUCED EMESIS; COGNITION; CONCENTRATION RESPONSE; DEMENTIA; DEPOLARIZATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ELECTRIC POTENTIAL; GLUCOSE METABOLISM; HIPPOCAMPUS; HOMEOSTASIS; HUMAN; IC 50; LATENT PERIOD; LEARNING; LEARNING DISORDER; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MAZE TEST; MEMORY; MICRODIALYSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REVIEW; SIGNAL NOISE RATIO; WORKING MEMORY;

ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGENTS; HOMEOSTASIS; HUMANS; MEMANTINE; MEMORY; MEMORY DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34948842904     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.07.013     Document Type: Review

References (238)

1. Abraham W.C., and Mason S.E. Effects of NMDA receptor/channel antagonists CPP and MK-801 on hippocampal field potentials and long-term potentiation in anasthetized rats. Brain Res. 462 (1988) 40-46
2. Albin R.L., and Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 42 (1992) 733-738
3. Alessandri-Haber N., Dina O.A., Joseph E.K., Reichling D., and Levine J.D. A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators. J. Neurosci. 26 (2006) 3864-3874
4. Andine P., Sandberg M., Bagenholm R., Lehmann A., and Hagberg H. Intra- and extracellular changes of amino acids in the cerebral cortex of the neonatal rat during hypoxic-ischemia. Dev. Brain Res. 64 (1991) 115-120
5. Andrasi E., Igaz S., Molnar Z., and Mako S. Disturbances of magnesium concentrations in various brain areas in Alzheimer's disease. Magnes. Res. 13 (2000) 189-196
6. Aracava, Y., Pereira, E.F., Maelicke, A., Albuquerque, E.X., 2004. Memantine at clinically relevant concentrations blocks more potently α7 nicotinic than NMDA receptors: implications for treatment of Alzheimer's disease, P1-416.
7. Aracava Y., Pereira E.F., Maelicke A., and Albuquerque E.X. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl-d-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 312 (2005) 1195-1205
8. Avenet P., Leonardon J., Besnard F., Graham D., Depoortere H., and Scatton B. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1a/NR2A and NR1a/NR2B receptors expressed in Xenopus oocytes. Neurosci. Lett. 223 (1997) 133-136
9. Bachurin S., Tkachenko S., Baskin I., Lermontova N., Mukhina T., Petrova L., Ustinov A., Proshin A., Grigoriev V., Lukoyanov N., Palyulin V., and Zefirov N. Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs. Structure-activity relationships. Ann. N. Y. Acad. Sci. 939 (2001) 219-236
10. Bakchine, S., Pascual-Gangnant L., Loft, H., 2005. Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. ADIS title: memantine: therapeutic use, Alzheimer's disease in patients with mild to moderate illness 2087.
11. Barber T.A., McGettigan B.F., and Meyers R.A. The effects of memantine on memory formation for passive avoidance learning in day - old chicks. Soc. Neurosci. Abst. 28 (2002) 684.6
12. Bardgett M.E., Schultheis P.J., McGill D.L., Richmond R.E., and Wagge J.R. Magnesium deficiency impairs fear conditioning in mice. Brain Res. 1038 (2005) 100-106
13. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., and Hillen H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95 (2005) 834-847
14. Barnes C.A., Danysz W., and Parsons C.G. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci. 8 (1996) 565-571
15. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol 38 (1995) 357-366
16. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23 (2000) 298-304
17. Benveniste H., Drejer J., Schusboe A., and Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43 (1984) 1369-1374
18. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. CD005593 (2006)
19. Black M., Lanthorn T., Small D., Mealing G., Lam V., and Morley P. Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. Eur. J. Pharmacol. 317 (1996) 377-381
20. Blanchard B.J., Park T., Fripp W.J., Lerman L.S., and Ingram V.M. A mitochondrial DNA deletion in normally aging and in Alzheimer brain tissue. Neuroreport 4 (1993) 799-802
21. Blanchard B.J., Thomas V.L., and Ingram V.M. Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem. Biophys. Res. Commun. 293 (2002) 1197-1203
22. Blanpied T.A., Boeckman F.A., Aizenman E., and Johnson J.W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77 (1997) 309-323
23. Blass J.P., Sheu R.K., and Gibson G.E. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. N. Y. Acad. Sci. 903 (2000) 204-221
24. Bormann J. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166 (1989) 591-592
25. Bowen D.M., Francis P.T., and Sims N.R. Beta-amyloid increased neuronal susceptibility to injury by glucose deprivation. Neuroreport 3 (1992) 733
26. Bresink I., Benke T.A., Collett V.J., Seal A.J., Parsons C.G., Henley J.M., and Collingridge G.L. Effects of memantine on recombinant rat NMDA receptors expressed in HEK-293 cells. Br. J. Pharmacol. 119 (1996) 195-204
27. Bresink I., Danysz W., Parsons C.G., and Mutschler E. Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 34 (1995) 533-540
28. Brewer G.J., and Wallimann T.W. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J. Neurochem. 74 (2000) 1968-1978
29. Brorson J.R., Bindokas V.P., Iwama T., Marcuccilli C.J., Chisholm J.C., and Miller R.J. The ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J. Neurobiol. 26 (1995) 325-338
30. Buisson A., Callebert J., Mathieu E., Plotkine M., and Boulu R.G. Striatal protection induced by lesioning the substantia nigra of rats subjected to focal ischemia. J. Neurochem. 59 (1992) 1153-1157
31. Buisson B., and Bertrand D. Open-channel blockers at the human alpha 4 beta 2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53 (1998) 555-563
32. Bullock R. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis. Assoc. Disord. 20 (2006) 23-29
33. Burns A., O'Brien J., Auriacombe S., Ballard C., Broich K., Bullock R., Feldman H., Ford G., Knapp M., McCaddon A., Iliffe S., Jacova C., Jones R., Lennon S., McKeith I., Orgogozo J.M., Purandare N., Richardson M., Ritchie C., Thomas A., Warner J., Wilcock G., and Wilkinson D. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. 20 (2006) 732-755
34. Carvalho F.M., Pereira S.R., Pires R.G., Ferraz V.P., Romano-Silva M.A., Oliveira-Silva I.F., and Ribeiro A.M. Thiamine deficiency decreases glutamate uptake in the prefrontal cortex and impairs spatial memory performance in a water maze test. Pharmacol. Biochem. Behav. 83 (2006) 481-489
35. Chen H.S., and Lipton S.A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. (Lond.) 499 pt 1 (1997) 27-46
36. Chen H.S.V., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., and Lipton S.A. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine - therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12 (1992) 4427-4436
37. Chen H.S.V., Wang Y.F., Rayudu P.V., Edgecomb P., Neill J.C., Segal M.M., Lipton S.A., and Jensen F.E. Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86 (1998) 1121-1132
38. Chen Q.S., Wei W.Z., Shimahara T., and Xie C.W. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem. 77 (2002) 354-371
39. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23 (1992) 1261-1276
40. Clark B.A., and Brown R.S. Unsuspected morbid hypermagnesemia in elderly patients. Am. J. Nephrol. 12 (1992) 336-343
41. Clements J.D., Lester R.A.J., Tong G., Jahr C.E., and Westbrook G.L. The time course of glutamate in the synaptic cleft. Science 258 (1992) 1498-1501
42. Coan E.J., and Collingridge G.L. Characterization of an N-methyl-d-aspartate receptor component of synaptic transmission in rat hippocampal slice. Neuroscience 22 (1987) 1-8
43. Coan E.J., Irving A.J., and Collingridge G.L. Low-frequence activation of the NMDA receptor system can prevent the induction of LTP. Neurosci. Lett. 105 (1989) 205-210
44. Cohn J., and Coryslechta D.A. Lead exposure potentiates the effects of NMDA on repeated learning. Neurotoxicol. Teratol. 16 (1994) 455-465
45. Collingridge G.L., and Bliss T.V.P. Memories of NMDA receptors and LTP. Trends Neurosci. 18 (1995) 54-56
46. Copani A., Koh J.Y., and Cotman C.W. B-amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport 2 (1991) 763-765
47. Costello D.A., and Herron C.E. The role of c-Jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus. Neuropharmacology 46 (2004) 655-662
48. Crawford J.G. Alzheimer's disease risk factors as related to cerebral blood flow. Med. Hypotheses 46 (1996) 367-377
49. Creeley C., Wozniak D.F., Labruyere J., Taylor G.T., and Olney J.W. Low doses of memantine disrupt memory in adult rats. J. Neurosci. 26 (2006) 3923-3932
50. Cummings J.L., Schneider E., Tariot P.N., and Graham S.M. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67 (2006) 57-63
51. Dantoine T., Auriacombe S., Sarazin M., Becker H., Pere J.J., and Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract. 60 (2006) 110-118
52. Danysz W., Essmann U., Bresink I., and Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48 (1994) 111-118
53. Danysz W., and Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease preclinical evidence. Int. J. Geriatr. Psychiatry 18 (2003) S23-S32
54. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., and Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21 (1997) 455-468
55. Danysz W., Parsons C.G., Möbius H.J., Stöffler A., and Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - an unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2 (2000) 85-97
56. Danysz W., Zajaczkowski W., and Parsons C.G. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6 (1995) 455-474
57. Davies S.N., Martin D., Millar J.D., Aram J.A., Church J., and Lodge D. Differences in results from in vivo and in vitro studies on the use-dependency of N-methyl-aspartate antagonism by MK-801 and other phencyclidine receptor ligands. Eur. J. Pharmacol. 145 (1988) 141-152
58. De Felice F.G., Velasco P.T., Lambert M.P., Viola K.L., Fernandez S.J., Ferreira S.T., and Klein W.L. A beta oligomers induce neuronal oxidative stress through an NMDA receptor-dependent mechanism that is blocked by the Alzheimer's drug memantine. J. Biol. Chem. 282 15 (2007) 11590-11601
59. De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Bigio, E.H., Jerecic, J., Acton, P.J., Shughrue, P.J., Chen-Dodson, E., Kinney, G.G., Klein, W.L., 2007b. Alzheimer's disease-type neuronal Tau hyperphosphorylation induced by Abeta oligomers. Neurobiol. Aging.
60. Delatorre J.C. Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci. Biobehav. Rev. 18 (1994) 397-401
61. Dickey C.A., Gordon M.N., Wilcock D.M., Herber D.L., Freeman M.J., and Morgan D. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci. 6 (2005) 7
62. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41 (1991) 773-780
63. Doody R., Wirth Y., Schmitt F., and Mobius H.J. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 18 (2004) 227-232
64. Doody R.S., Tariot P.N., Pfeiffer E., Olin J.T., Graham S.M., and Bell J.M. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. Ann. Neurol. 58 suppl. 9 (2005) 49-50
65. Durlach J. Magnesium depletion and pathogenesis of Alzheimer's disease. Magnes. Res. 3 (1990) 217-218
66. van Dyck C.H., Schmitt F.A., and Olin J.T. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am. J. Geriatr. Psychiatry 14 (2006) 428-437
67. Elgoyhen A.B., Vetter D.E., Katz E., Rothlin C.V., Heinemann S.F., and Boulter J. Alpha 10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3501-3506
68. Emerit J., Edeas M., and Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58 (2004) 39-46
69. Enz A., and Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 47 (2004) 408-413
70. Ferris S.H. Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. 4 (2003) 2305-2313
71. Floden A.M., Li S., and Combs C.K. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J. Neurosci. 25 (2005) 2566-2575
72. Franceschi M., Alberoni M., Bressi S., Canal N., Comi G., Fazio F., Grassi F., Perani D., and Volonte M.A. Correlations between cognitive impairment, middle cerebral artery flow velocity and cortical glucose metabolism in the early phase of Alzheimer's disease. Dementia 6 (1995) 32-38
73. Frankiewicz T., and Parsons C.G. Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 38 (1999) 1253-1259
74. Frankiewicz T., Potier B., Bashir Z.I., Collingridge G.L., and Parsons C.G. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. 117 (1996) 689-697
75. Freir D.B., Holscher C., and Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 85 (2001) 708-713
76. Fung M.C., Weintraub M., and Bowen D.L. Hypermagnesemia. Elderly over-the-counter drug users at risk. Arch. Fam. Med. 4 (1995) 718-723
77. Furukawa K., and Mattson M.P. Secreted amyloid precursor protein alpha selectively suppresses N-methyl-d-aspartate currents in hippocampal neurons: involvement of cyclic GMP. Neuroscience 83 (1998) 429-438
78. Gauthier S., Wirth Y., and Mobius H.J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 20 (2005) 459-464
79. Gerzon K., Krumkalns E.V., Brindle R.L., Marshall F.J., and Root M.A. The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N′-adamantylureas. J. Med. Chem. 6 (1963) 760-763
80. Gilling K.E., Jatzke C., and Parsons C.G. Agonist concentration-dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine. Neuropharmacology 53 (2007) 415-420
81. Glick J.L. Dementias: the role of magnesium deficiency and an hypothesis concerning the pathogenesis of Alzheimer's disease. Med. Hypotheses 31 (1990) 211-225
82. Globus M.Y.T., Busto R., Martinez E., Valdes I., Dietrich W.D., and Ginsberg M.D. Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine, and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. J. Neurochem. 57 (1991) 470-478
83. Globus M.Y.T., Ginsberg M.D., and Busto R. Excitotoxic index - a biochemical marker of selective vulnerability. Neurosci. Lett. 127 (1991) 39-42
84. Golde T.E. Disease modifying therapy for AD?. J. Neurochem. 99 (2006) 689-707
85. Goto I., Taniwaki T., Hosokawa S., Otsuka M., Ichiya Y., and Ichimiya A. Positron emission tomographic (PET) studies in dementia. J. Neurol. Sci. 114 (1993) 1-6
86. Grant K.A., Colombo G., Grant J., and Rogawski M.A. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35 (1996) 1709-1719
87. Greenamyre J.T. Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease - use it and lose it. Neurobiol. Aging 12 (1991) 334-336
88. Grimwood S., Gilbert E., Ragan C.I., and Hutson P.H. Modulation of 45Ca2+ influx into cells stably expressing recombinant human NMDA receptors by ligands acting at distinct recognition sites. J. Neurochem. 66 (1996) 2589-2595
89. Hallak M. Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. Magnes. Res. 11 (1998) 117-131
90. Harris M.E., Wang Y.N., Pedigo N.W., Hensley K., Butterfield D.A., and Carney J.M. Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J. Neurochem. 67 (1996) 277-286
91. Hartmann S., and Mobius H.J. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol. 18 (2003) 81-85
92. Hattori N., Kitagawa K., Higashida T., Yagyu K., Shimohama S., Wataya T., Perry G., Smith M.A., and Inagaki C. CI-ATPase and Na+/K(+)-ATPase activities in Alzheimer's disease brains. Neurosci. Lett. 254 (1998) 141-144
93. Henneberry R.C. The role of neuronal energy in the neurotoxicity of excitatory amino acids. Neurobiol. Aging 10 (1989) 611-613
94. Herrero J.F., Headley P.M., and Parsons C.G. Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo. Neurosci. Lett. 165 (1994) 37-40
95. Herron C.E., Lester R.A.J., Coan E.J., and Collingridge G.L. Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism. Nature 322 (1986) 265-269
96. Hesselink M.B., DeBoer B.G., Breimer D.D., and Danysz W. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm. Res. 16 (1999) 637-642
97. Hesselink M.B., Smolders H., DeBoer A.G., Breimer D.D., and Danysz W. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration. Behav. Pharmacol. 10 (1999) 85-98
98. Hesselink M.B., Smolders H., Eilbacher B., DeBoer A.G., Breimer D.D., and Danysz W. The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-d-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. J. Pharmacol. Exp. Ther. 290 (1999) 543-550
99. Hirai H., Kirsch J., Laube B., Betz H., and Kuhse J. The glycine binding site of the N-methyl-d-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular m3-m4 loop region. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 6031-6036
100. Honegger U.E., Quack G., and Wiesmann U.N. Evidence for lysosomotropism of memantine in cultured human cells - cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacol. Toxicol. 73 (1993) 202-208
101. Howland J.G., Wong T., Fox C.J., Ge Y., Russell K.I., Brebner K., Phillips A.G., Weinberg J., Christie B.R., and Wang Y. Stress-induced spatial memory disruption depends on long-term depression in the hippocampus. Soc. Neurosci. Abst. 32 (2006) 266.16
102. Hoyer S. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol. Scand. 93 (1996) 18-24
103. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 35 (2000) 1363-1372
104. Hoyer S., and Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J. Neural Transm. - Gen. Sect. 75 (1989) 227-232
105. Hoyer S., Nitsch R., and Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type - a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J. Neural Transm. 3 (1991) 1-14
106. Hutchin T., and Cortopassi G. A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 6892-6895
107. Izumi Y., Clifford D.B., and Zorumski C.F. Low concentrations of N-methyl-d-aspartate inhibit the induction of long-term potentiation in rat hippocampal slices. Neurosci. Lett. 137 (1992) 245-248
108. Johnson J.W., and Kotermanski S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 6 (2006) 61-67
109. Jones K.W., Schaeffer C.L., and DeNoble V.J. Systemically administered N-methyl-d-aspartate interferes with acquisition of passive avoidance response in rats. Pharmacol. Biochem. Behav. 34 (1989) 181-186
110. Jones M.W., McClean M., Parsons C.G., and Headley P.M. The in vivo significance of the varied channel blocking properties of uncompetitive NMDA receptor antagonists. Neuropharmacology 41 (2001) 50-61
111. Kairane C., Roots K., Uusma T., Bogdanovic N., Karelson E., Koks S., and Zilmer M. Regulation of the frontocortical sodium pump by Na+ in Alzheimer's disease: difference from the age-matched control but similarity to the rat model. FEBS Lett. 531 (2002) 241-244
112. Katagiri H., Tanaka K., and Manabe T. Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. Eur. J. Neurosci. 14 (2001) 547-553
113. Katz E., Elgoyhen A.B., Gomez-Casati M.E., Knipper M., Vetter D.E., Fuchs P.A., and Glowatzki E. Developmental regulation of nicotinic synapses on cochlear inner hair cells. J. Neurosci. 24 (2004) 7814-7820
114. Keller J.N., Pang Z., Geddes J.W., Begley J.G., Germeyer A., Waeg G., and Mattson M.P. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69 (1997) 273-284
115. Kennedy A.M., Frackowiak R.S.J., Newman S.K., Bloomfield P.M., Seaward J., Roques P., Lewington G., Cunningham V.J., and Rossor M.N. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186 (1995) 17-20
116. Kew J.N.C., Trube G., and Kemp J.A. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br. J. Pharmacol. 123 (1998) 463-472
117. Kim J.H., Anwyl R., Suh Y.H., Djamgoz M.B., and Rowan M.J. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 21 (2001) 1327-1333
118. Kinsley C.H., Madonia L., Gifford G.W., Tureski K., Griffin G.R., Lowry C., Williams J., Collins J., McLearie H., and Lambert K.G. Motherhood improves learning and memory. Nature 402 (1999) 137-138
119. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 (2004) 569-580
120. Kornhuber J., Mack-Burkhardt F., Kornhuber M.E., and Riederer P. [3H]MK-801 binding sites in post-mortem human frontal cortex. Eur. J. Pharmacol. 162 (1989) 483-490
121. Kornhuber J., and Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 195 (1995) 137-139
122. Kornhuber J., and Weller M. Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 41 (1997) 135-144
123. Kotermanski S.E., and Johnson J.W. Partial trapping of memantine by NMDA receptors. Soc. Neurosci. Abst. 30 (2004) 731.7
124. Kwong J.Q., Beal M.F., and Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 97 (2006) 1659-1675
125. Lacor P.-N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., and Klein W.L. Aβ oligomers-induced aberrations in synapse composition, shape and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27 (2007) 796-807
126. Ladner C.J., and Lee J.M. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 158 (1999) 451-458
127. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A 95 (1998) 6448-6453
128. Lanctot K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., LouLou M.M., and Einarson T.R. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169 (2003) 557-564
129. Landfield P.W., and Morgan G.A. Chronically elevating plasma Mg2+ improves hippocampal frequency potentiation and reversal learning in aged and young rats. Brain Res. 322 (1984) 167-171
130. Lanthorn T.H., Mealing G.A.R., and Morley P. Differences in degree of trapping between AR-R15896 and other uncompetitive NMDA receptor antagonists. Amino Acids 19 (2000) 173-175
131. Laube B., Hirai H., Sturgess M., Betz H., and Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18 (1997) 493-503
132. Lesne S., Ali C., Gabriel C., Croci N., MacKenzie E.T., Glabe C.G., Plotkine M., Marchand-Verrecchia C., Vivien D., and Buisson A. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J. Neurosci. 25 (2005) 9367-9377
133. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
134. Li J.H., Wang Y.H., Wolfe B.B., Krueger K.E., Corsi L., Stocca G., and Vicini S. Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical. Eur. J. Neurosci. 10 (1998) 1704-1715
135. Lipton S.A. Turning down, but not off. Nature 428 (2004) 473
136. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2 (2005) 155-165
137. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5 (2006) 160-170
138. Lipton S.A., and Chen H.S. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 11 (2004) 18-20
139. Luhrs, L.B., Banerjee, P.K., LeFerla, F.M., 2006. Memantine reverses cognitive deficits in transgenic mice with both plaques and tangles, P1-001.
140. Lukoyanov N.V., and Paula-Barbosa M.M. Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Neurosci. Lett. 309 (2001) 45-48
141. Maskell P.D., Speder P., Newberry N.R., and Bermudez I. Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-d-aspartate receptors. Br. J. Pharmacol. 140 (2003) 1313-1319
142. Masliah E., Raber J., Alford M., Mallory M., Mattson M.P., Yang D., Wong D., and Mucke L. Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. J. Biol. Chem. 273 (1998) 12548-12554
143. Mattson M.P., Barger S.W., Cheng B., Lieberburg I., Smithswintosky V.L., and Rydel R.E. β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16 (1993) 409-414
144. McShane R., Areosa Sastre A., and Minakaran N. Memantine for dementia. Cochrane Database Syst. Rev. CD003154 (2006)
145. Mecocci P., Macgarvey U., and Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36 (1994) 747-751
146. Mielke R., Herholz K., Grond M., Kessler J., and Heiss W.D. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol. Aging 13 (1992) 93-98
147. Miguel-Hidalgo J., Paul I., Wanzo V., Hachicha M., and Banerjee P. Memantine inhibits the expression of caspase-8 and improves learning in rats injected with β-amyloid (Aβ1-40). Soc. Neurosci. Abst. 31 (2005) 1019.5
148. Minkeviciene R., Banerjee P., and Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 311 (2004) 677-682
149. Misztal M., Frankiewicz T., Parsons C.G., and Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine. Eur. J. Pharmacol. 296 (1996) 1-8
150. Mitani A., Andou Y., and Kataoka K. Selective vulnerability of hippocampal CA1 neurons cannot be explained in terms of an increase in glutamate concentration during ischemia in the gerbil: brain microdialysis study. Neuroscience 48 (1992) 307-313
151. Molinuevo J.L. Memantine. Neurologia 18 (2003) 255-261
152. Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (1994) 529-540
153. Morris R.G.M., Anderson E., Lynch G.S., and Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 319 (1986) 774-776
154. Nakagami Y., and Oda T. Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. Jpn J. Pharmacol. 88 (2002) 223-226
155. Nakamura S., Murayama N., Noshita T., Katsuragi R., and Ohno T. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. Eur. J. Pharmacol. 548 (2006) 115-122
156. Nankai M., Klarica M., Fage D., and Carter C. The pharmacology of native N-methyl-d-aspartate receptor subtypes: different receptors control the release of different striatal and spinal transmitters. Prog. Neuropsychopharmacol. Biol. Psychiatry 22 (1998) 35-64
157. Noda M., Nakanishi H., and Akaike N. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 92 (1999) 1465-1474
158. Nomura I., Kato N., Kita T., and Takechi H. Mechanism of impairment of long-term potentiation by amyloid beta is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci. Lett. 391 (2005) 1-6
159. Novelli A., Reilly J.A., Lysko P.G., and Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451 (1988) 205-212
160. Nowak L., Bregestovski P., Ascher P., Herbert A., and Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurons. Nature 307 (1984) 462-465
161. Nyakas, C., Szabó, R., Penke, B., Banerjee, P., Luiten, P.G.M., 2006. Memantine rescues cholinergic neurons from the neurotoxic effects of β-amyloid (Aβ1-42) P4-305.
162. Oliver D., Ludwig J., Reisinger E., Ruppersberg J.P., and Fakler B. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking heteromeric alpha9/alpha10 acetylcholine receptors of outer hair cells. Pfluegers Arch. Eur. J. Physiol. 441 (2001) R203
163. Orgogozo J.M., Rigaud A.S., Stoffler A., Mobius H.J., and Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33 (2002) 1834-1839
164. Ozturk S., and Cillier A.E. Magnesium supplementation in the treatment of dementia patients. Med. Hypotheses 67 (2006) 1223-1225
165. ParpuraGill A., Beitz D., and Uemura E. The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res. 754 (1997) 65-71
166. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11 (1998) 523-569
167. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., and Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38 (1999) 85-108
168. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38 (1999) 735-767
169. Parsons, C.G., Gilling, K.E., Jatzke, C. Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes. Eur. J. Pharmacol., submitted for publication.
170. Parsons C.G., Gruner R., Rozental J., Millar J., and Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32 (1993) 1337-1350
171. Parsons C.G., Hartmann S., and Spielmanns P. Budipine is a low affinity, N-methyl-d-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. Neuropharmacology 37 (1998) 719-727
172. Parsons C.G., Panchenko V.A., Pinchenko V.O., Tsyndrenko A.Y., and Krishtal O.A. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci. 8 (1996) 446-454
173. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., and Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34 (1995) 1239-1258
174. Periclou A.P., Ventura D., Sherman T., Rao N., and Abramowitz W.T. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann. Pharmacother. 38 (2004) 1389-1394
175. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., and McDonald S. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am. J. Geriatr. Psychiatry 14 (2006) 704-715
176. Porter R.H.P., and Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64 (1995) 614-623
177. Puzzo D., and Arancio O. Fibrillar beta-amyloid impairs the late phase of long term potentiation. Curr. Alzheimer Res. 3 (2006) 179-183
178. Quack G., Hesselink M., Danysz W., and Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J. Neural Transm. Suppl. 46 (1995) 97-105
179. 3 receptor currents in HEK-293 and N1E-115 cells in a non-competitive manner. Neurosci. Lett. 306 (2001) 81-84
180. Rammsayer T.H. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn. Mem. 8 (2001) 20-25
181. Raschetti R., Maggini M., Sorrentino G.C., Martini N., Caffari B., and Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur. J. Clin. Pharmacol. 61 (2005) 361-368
182. Raymond C.R., Ireland D.R., and Abraham W.C. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 968 (2003) 263-272
183. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 (2003) 1333-1341
184. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists - channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14 (1993) 325-331
185. Rogawski M.A., and Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9 (2003) 275-308
186. Rogawski M.A., Yamaguchi S.I., Jones S.M., Rice K.C., Thurkauf A., and Monn J.A. Anticonvulsant activity of the low-affinity uncompetitive N-methyl-d-aspartate antagonist (+/-)-5-aminocarbonyl-10,11-dihydro-5H-dibenzocyclohepten-5, 10-imine (ADCI) - comparison with the structural analogs dizocilpine (mK-801) and carbamazepine. J. Pharmacol. Exp. Ther. 259 (1991) 30-37
187. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 (1984) 1356-1364
188. Rowan M.J., Klyubin I., Cullen W.K., and Anwyl R. Synaptic plasticity in animal models of early Alzheimer's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358 (2003) 821-828
189. Rowan M.J., Klyubin I., Wang Q., and Anwyl R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp. Gerontol. 39 (2004) 1661-1667
190. Rowan M.J., Klyubin I., Wang Q., and Anwyl R. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem. Soc. Trans. 33 (2005) 563-567
191. Saxton J., McGonigle K.L., Swihart A.A., and Boller F. The severe impairment battery. In: Suffolk (Ed). The University of Pittsburgh of the Commonwealth System of Higher Education (1993), Thames Valley Test Company 1-16
192. Schmitt F.A., Ashford J.W., Ferris S., Mackell S.J., Schneider L., et al. Severe impairment battery: a potential measure for AD clinical trials. In: Becker R., and Giacobini E. (Eds). Alzheimer Disease: From Molecular Biology to Therapy (1996), Birkhäuser, Boston 419-423
193. Schmitt F.A., Cragar D., Ashford J.W., Reisberg B., Ferris S., and Mobius H.J. Measuring cognition in advanced Alzheimer's disease for clinical trials. Stoffler AdJ. Neural Transm. Suppl. 62 (2002) 135-148
194. Schmitt F.A., van Dyck C.H., Wichems C.H., and Olin J.T. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis. Assoc. Disord. 20 (2006) 255-262
195. Schugens M.M., Egerter R., Daum I., Schepelmann K., Klockgether T., and Loschmann P.A. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci. Lett. 224 (1997) 57-60
196. Si A., Helliwell P., and Maleszka R. Effects of NMDA receptor antagonists on olfactory learning and memory in the honeybee (Apis mellifera). Pharmacol. Biochem. Behav. 77 (2004) 191-197
197. Simpson I.A., Chundu K.R., Davieshill T., Honer W.G., and Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with alzheimers disease. Ann. Neurol. 35 (1994) 546-551
198. Sobolevsky A., and Koshelev S. Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels. Biophys. J. 74 (1998) 1305-1319
199. Sobolevsky A.I., Koshelev S.G., and Khodorov B.I. Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J. Physiol. (Lond.) 512 pt 1 (1998) 47-60
200. Spanagel R., Eilbacher B., and Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmacokinetic microdialysis study. Eur. J. Pharmacol. 262 (1994) 21-26
201. Sucher N.J., Akbarian S., Chi C.L., Leclerc C.L., Awobuluyi M., Deitcher D.L., Wu M.K., Yuan J.P., Jones E.G., and Lipton S.A. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-l) in the rodent brain. J. Neurosci. 15 (1995) 6509-6520
202. Takeda A., Loveman E., Clegg A., Kirby J., Picot J., Payne E., and Green C. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int. J. Geriatr. Psychiatry 21 (2006) 17-28
203. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
204. Thompson S., Lanctot K.L., and Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin. Drug Saf. 3 (2004) 425-440
205. de la Torre J.C., and Stefano G.B. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain. Res. Rev. 34 (2000) 119-136
206. Townsend M., Shankar G.M., Mehta T., Walsh D.M., and Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572 (2006) 477-492
207. Van Dam D., Abramowski D., Staufenbiel M., and De Deyn P.P. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl.) 180 (2005) 177-190
208. Van Dam D., and De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur. Neuropsychopharmacol. 16 (2006) 59-69
209. Vignini A., Nanetti L., Moroni C., Tanase L., Bartolini M., Luzzi S., Provinciali L., and Mazzanti L. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol. Aging 28 7 (2006) 987-994
210. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
211. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
212. Walsh D.M., Townsend M., Podlisny M.B., Shankar G.M., Fadeeva J.V., El Agnaf O., Hartley D.M., and Selkoe D.J. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25 (2005) 2455-2462
213. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., and Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924 (2002) 133-140
214. Wang Q., Rowan M.J., and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24 (2004) 6049-6056
215. Wang Q., Walsh D.M., Rowan M.J., Selkoe D.J., and Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24 (2004) 3370-3378
216. Wang Q., Wu J., Rowan M.J., and Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur. J. Neurosci. 22 (2005) 2827-2832
217. Wary C., Brillault-Salvat C., Bloch G., Leroy-Willig A., Roumenov D., Grognet J.M., Leclerc J.H., and Carlier P.G. Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes. Br. J. Clin. Pharmacol. 48 (1999) 655-662
218. Wenk G.L., Danysz W., and Mobley S.L. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res. 655 (1994) 7-11
219. Wenk G.L., Danysz W., and Roice D.D. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport 7 (1996) 1453-1456
220. Wenk G.L., Parsons C.G., and Danysz W. Potential role of NMDA receptors as executors of neurodegeneration resulting from diverse insults focus on memantine. Behav. Pharmacol. 17 (2006) 411-424
221. Wesemann W., and Ekenna O. Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelforschung 32 (1982) 1241-1243
222. Wesemann W., Schollmeyer J.D., and Sturm G. Distribution of Memantine in brain, Liver, and blood of the rat. Arzneimittelforschung 32 (1982) 1243-1245
223. Wesemann W., Sturm G., and Funfgeld E.W. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. J. Neural Transm. Suppl. 16 (1980) 143-148
224. Wilcock G., Mobius H.J., and Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. 17 (2002) 297-305
225. Willard L.B., Hauss-Wegrzyniak B., Danysz W., and Wenk G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 134 (2000) 58-65
226. Winblad B., and Poritis N. Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia. Neurobiol. Aging 19 (1998) S303
227. Wu J.Q., Anwyl R., and Rowan M.J. beta-amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 6 (1995) 2409-2413
228. Xiong H., McCabe L., Costello J., Anderson E., Weber G., and Ikezu T. Activation of NR1a/NR2B receptors by soluble factors from APP-stimulated monocyte-derived macrophages: implications for the pathogenesis of Alzheimer's disease. Neurobiol. Aging 25 (2004) 905-911
229. Yamada K., Takayanagi M., Kamei H., Nagai T., Dohniwa M., Kobayashi K., Yoshida S., Ohhara T., Takauma K., and Nabeshima T. Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav. Brain Res. 162 (2005) 191-199
230. Yang L.S., and Ksiezak-Reding H. Ca2+ and Mg2+ selectively induce aggregates of PHF-Tau but not normal human Tau. J. Neurosci. Res. 55 (1999) 36-43
231. Ye C., Walsh D.M., Selkoe D.J., and Hartley D.M. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci. Lett. 366 (2004) 320-325
232. Ye L., and Qiao J.T. Suppressive action produced by beta-amyloid peptide fragment 31-35 on long-term potentiation in rat hippocampus is N-methyl-d-aspartate receptor-independent: it's offset by (-)huperzine A. Neurosci. Lett. 275 (1999) 187-190
233. Zajaczkowski W., Frankiewicz T., Parsons C.G., and Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36 (1997) 961-971
234. Zajaczkowski W., Hetman M., Nikolaev E., Quack G., Danysz W., and Kaczmarek L. Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists. Neurotox. Res. 1 (2000) 299-310
235. Zajaczkowski W., Moryl E., and Papp M. Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats. Pharmacol. Biochem. Behav. 55 (1996) 163-168
236. Zajaczkowski W., Quack G., and Danysz W. Infusion of (+)-MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296 (1996) 239-246
237. Zakharova E., Danysz W., and Bespalov A. Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats. Psychopharmacology 179 (2005) 128-135
238. Zoladz P.R., Campbell A.M., Park C.R., Schaefer D., Danysz W., and Diamond D.M. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol. Biochem. Behav. 85 (2006) 298-306